KA/EN
Register
Medicines reference
Search
Search
Active substance

Carbethopendecinium bromide

Favourites

Quaternary ammonium antiseptic. Registered in Georgia: 1 veterinary product. Forms: ear drops.

Dose and use

Doses

We have no dose with a cited source for this substance yet.

Before use

Safety information

Known Contraindications

  • Critical
    Do not use in hypersensitivity to the substance, the other components or corticosteroids.
    Sources: Czech SPC
Latin name
Carbethopendecinium bromide
Georgian name
კარბეთოპენდეცინიუმის ბრომიდი
Authorisation status
Authorised veterinary medicine
An authorised veterinary medicine containing this substance exists. Whether a particular use is on-label depends on the species and the indication - see each dose rule.
Registered in Georgia
1 of 1 forms
Products
Otibiovin
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 18 Oct 2026
All forms and registration1

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Otibiovin, Ear drops

triamcinolone acetonide 0.5 mg + salicylic acid 5 mg + gentamicin sulfate 2 mg + carbethopendecinium bromide 0.125 mg per ml, ear drops
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Label-concordant treatment of severe canine external otitis caused by susceptible organisms, with intact tympanum, diagnostic support and primary-cause management
6.0/10
Situational / acceptable
vetman assessment

Otibiovin

triamcinolone acetonide 0.5 mg + salicylic acid 5 mg + gentamicin sulfate 2 mg + carbethopendecinium bromide 0.125 mg per ml, ear drops
Assessed clinical scopeDog · Label-concordant treatment of severe canine external otitis caused by susceptible organisms, with intact tympanum, diagnostic support and primary-cause management · Into the ear
Care settingVeterinary otoscopy and cytology before cleaning, intact-tympanum confirmation, susceptibility-led selection for severe/recurrent infection, instructed high-frequency home treatment and planned clinical/cytological recheck
vetman score 6.0/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, veterinary · Verified on 22 Oct 2026

A transparent authorised option for a narrow, diagnosed susceptible canine otitis role, but not an empirical all-purpose ear drop: intact tympanum, susceptibility, primary-cause treatment and demanding frequent dosing determine value.

Regulatory and scientific credibility7.5/10

The exact dog/cat formulation, dose, strict indication restriction and 12-day open life are transparent, with current Georgian and Czech/EU authorisation. The regulator document is old and no independent exact-product trial or broad pharmacovigilance record was identified.

Clinical efficacy6.0/10

Gentamicin, anti-inflammatory triamcinolone, salicylic acid and cationic antiseptic are mechanistically coherent for selected susceptible otitis. Historical isolates showed 90% overall and 85% Pseudomonas gentamicin susceptibility, not universal coverage; no exact-product trial and no conventional dedicated antifungal limit confidence.

Safety and tolerability5.5/10

An intact tympanum materially reduces risk, and the exact label reports no known adverse effects, but topical gentamicin remains potentially ototoxic. Steroid masking/immunosuppression, irritation from salicylic acid/ethanol/antiseptic, low systemic antibiotic exposure and a painful diseased canal require active monitoring.

Clinical practicality4.5/10

Four to five drops three to four times daily, then two to three times daily, plus cleaning/massage for up to 12 days is measurable but demanding for home adherence. Pain, canal stenosis, resistant infection and frequent handling may make treatment unreliable without demonstration and early recheck.

Full-course cost-effectiveness-

Current Georgian full-course price and presentation-specific wastage cost were unavailable; price is excluded from the denominator.

Important safety and use flags

  • Hard stop: confirm an intact tympanic membrane before use. Do not use with rupture or when middle-ear exposure cannot be responsibly excluded. Gentamicin may be ototoxic, especially beyond an abnormal tympanum.
  • Obtain cytology before cleaning and diagnose the primary cause. The exact label restricts use to serious infection supported by pathogen identification, susceptibility to the active and resistance to common antibiotics; do not use as an empirical all-purpose ear drop.
  • Dose is 4–5 drops into the affected external canal 3–4 times daily initially, then 2–3 times daily after three days; massage gently. Usual duration is 5–7 days and the absolute label maximum is 12 days.
  • Recheck clinically and cytologically. Stop and urgently assess new hearing loss, head tilt, nystagmus, ataxia, vertigo, facial-nerve change, marked pain or worsening discharge; investigate otitis media rather than continuing blindly.
  • Gentamicin susceptibility is not universal and historical Pseudomonas coverage was about 85%. Culture/susceptibility is especially important for rods, severe/recurrent disease, prior antimicrobial exposure or poor response; minimise resistance selection.
  • No conventional dedicated antifungal or acaricide is present. Treat confirmed yeast/fungal disease and Otodectes with an appropriate effective plan; in-vitro gentamicin inhibition of Malassezia is not clinical antifungal equivalence.
  • Triamcinolone can reduce inflammation and pain but can mask progression, delay healing, promote secondary infection and cause local/systemic glucocorticoid effects. Do not extend beyond 12 days or repeat courses without re-diagnosis.
  • Salicylic acid, ethanol and carbethopendecinium can irritate an eroded inflamed canal. Do not add another cleaner or drop unless compatibility, spacing and tympanic safety are established; avoid traumatic cleaning.
  • Low systemic antibiotic concentrations can occur after routine topical otic treatment. Consider total aminoglycoside exposure, renal/neuromuscular vulnerability and concurrent ototoxic drugs when the canal is severely inflamed or treatment is repeated.
  • Shake to redisperse permitted slight sediment, avoid dropper contact/cross-ear contamination, label first opening, store below 25 °C protected from light and discard after 12 days. Wear gloves, wash hands and avoid eye/skin/mucosal contact or ingestion.
Assessment sources
  1. Otibiovin Czech SPC2011
  2. Otibiovin exact2026
  3. MSD otitis externa2026
  4. Topical otic review2016
  5. Otitis susceptibility2006
  6. Otomax VMD control2026
  7. Otomax FDA control2026
  8. Otic systemic exposure2012
  9. Pseudomonas review2007
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Label-concordant treatment of severe feline external otitis caused by susceptible organisms, with intact tympanum, diagnostic support and primary-cause management
5.7/10
Weak evidence support
vetman assessment

Otibiovin

triamcinolone acetonide 0.5 mg + salicylic acid 5 mg + gentamicin sulfate 2 mg + carbethopendecinium bromide 0.125 mg per ml, ear drops
Assessed clinical scopeCat · Label-concordant treatment of severe feline external otitis caused by susceptible organisms, with intact tympanum, diagnostic support and primary-cause management · Into the ear
Care settingVeterinary otoscopy and cytology before cleaning, intact-tympanum confirmation, susceptibility-led selection for severe/recurrent infection, instructed high-frequency home treatment and planned clinical/cytological recheck
vetman score 5.7/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, veterinary · Verified on 22 Oct 2026

Authorised for cats, but direct feline outcomes are absent and the high-frequency gentamicin/steroid regimen has important diagnostic, ototoxicity, spectrum and handling constraints; reserve for well-supported susceptible cases.

Regulatory and scientific credibility7.5/10

The exact dog/cat formulation, dose, strict indication restriction and 12-day open life are transparent, with current Georgian and Czech/EU authorisation. The regulator document is old and no independent exact-product trial or broad pharmacovigilance record was identified.

Clinical efficacy5.0/10

The exact label includes cats and mixed-species susceptibility data support possible activity, but no independent feline Otibiovin outcome study was identified. Feline causes differ, gentamicin coverage is incomplete and the formula lacks a conventional dedicated antifungal.

Safety and tolerability5.5/10

An intact tympanum materially reduces risk, and the exact label reports no known adverse effects, but topical gentamicin remains potentially ototoxic. Steroid masking/immunosuppression, irritation from salicylic acid/ethanol/antiseptic, low systemic antibiotic exposure and a painful diseased canal require active monitoring.

Clinical practicality4.0/10

The same high-frequency schedule is particularly burdensome in many cats and can increase restraint stress, missed doses and dropper contamination. Feline-friendly handling, pain control, demonstration and an early recheck are central to feasibility.

Full-course cost-effectiveness-

Current Georgian full-course price and presentation-specific wastage cost were unavailable; price is excluded from the denominator.

Important safety and use flags

  • Hard stop: confirm an intact tympanic membrane before use. Do not use with rupture or when middle-ear exposure cannot be responsibly excluded. Gentamicin may be ototoxic, especially beyond an abnormal tympanum.
  • Obtain cytology before cleaning and diagnose the primary cause. The exact label restricts use to serious infection supported by pathogen identification, susceptibility to the active and resistance to common antibiotics; do not use as an empirical all-purpose ear drop.
  • Dose is 4–5 drops into the affected external canal 3–4 times daily initially, then 2–3 times daily after three days; massage gently. Usual duration is 5–7 days and the absolute label maximum is 12 days.
  • Recheck clinically and cytologically. Stop and urgently assess new hearing loss, head tilt, nystagmus, ataxia, vertigo, facial-nerve change, marked pain or worsening discharge; investigate otitis media rather than continuing blindly.
  • Gentamicin susceptibility is not universal and historical Pseudomonas coverage was about 85%. Culture/susceptibility is especially important for rods, severe/recurrent disease, prior antimicrobial exposure or poor response; minimise resistance selection.
  • No conventional dedicated antifungal or acaricide is present. Treat confirmed yeast/fungal disease and Otodectes with an appropriate effective plan; in-vitro gentamicin inhibition of Malassezia is not clinical antifungal equivalence.
  • Triamcinolone can reduce inflammation and pain but can mask progression, delay healing, promote secondary infection and cause local/systemic glucocorticoid effects. Do not extend beyond 12 days or repeat courses without re-diagnosis.
  • Salicylic acid, ethanol and carbethopendecinium can irritate an eroded inflamed canal. Do not add another cleaner or drop unless compatibility, spacing and tympanic safety are established; avoid traumatic cleaning.
  • Direct feline Otibiovin outcome evidence was not identified. Use feline-friendly restraint and analgesia, demonstrate dosing and reassess early; repeated forced treatment can make the high-frequency course impractical and unsafe.
  • Shake to redisperse permitted slight sediment, avoid dropper contact/cross-ear contamination, label first opening, store below 25 °C protected from light and discard after 12 days. Wear gloves, wash hands and avoid eye/skin/mucosal contact or ingestion.
Assessment sources
  1. Otibiovin Czech SPC2011
  2. Otibiovin exact2026
  3. MSD otitis externa2026
  4. Topical otic review2016
  5. Otitis susceptibility2006
  6. Feline otitis review2013
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Triamcinolone0.5 mg/ml Salicylic acid5 mg/ml Gentamicin2 mg/ml Carbethopendecinium bromide0.125 mg/ml
Formulation Type
Ear drops
Administration route
Into the ear
Manufacturer
Bioveta a.s. · Czechia
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ოტიბიოვინი
Verified on: 22 Oct 2026
 EU Yes, veterinary
№ 96/131/96-C
Verified on: 22 Oct 2026
 UK No
Verified on: 22 Oct 2026
 US No
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 18 Oct 2026
Information not fully verified Dogs/cats: after otoscopy, cytology, cleaning and intact-tympanum confirmation, instil 4–5 drops 3–4 times daily initially, then 2–3 times daily after three days; usually 5–7 days, maximum 12. Use only for a diagnosed susceptible serious infection under the exact label restriction. Treat the primary cause and recheck clinically/cytologically.

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗